MedTrace Logo

Tranexamic Acid for Total Knee Arthroscopy

NCT04443920 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2023-06-22

No results posted yet for this study

Summary

The purpose of this investigation is to determine the most effective regimen of administration of tranexamic acid to improve clinical outcome among patients undergoing total knee arthroplasty.

Conditions

  • Blood Loss, Surgical

Interventions

DRUG

Tranexamic acid (TXA)

Randomly assigned \[1:1 ratio\] using a computer generated table of random numbers to 1 of the 2 intervention groups

DRUG

Placebo Normal Saline (NS)

Randomly assigned \[1:1 ratio\] using a computer generated table of random numbers to 1 of the 2 intervention groups

Sponsors & Collaborators

  • The Miriam Hospital

    lead OTHER

Principal Investigators

  • Denis Snegovskikh, MD · Rhode Island Hospital; Brown University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-29
Primary Completion
2020-10-07
Completion
2021-01-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04443920 on ClinicalTrials.gov